| MCHUTCHINSON, John, Zachary GOODMAN, Keyur PATEL, Hala MAKLOUF, Maribel RODRIGUEZ-TORRES, Mitchel SCHIFFMAN, Ron ROCKEY, Petr HUSA, Wan-Long CHUANG, Robert LEVINE, Mark JONAS, Theodore DICKENS, Richard BRIGANDI, Alison WEBSTER, Margaret SCHULTZ, Helen WATSON, Britt STANCIL and Stephan GARDNER. Farglitazar lacks antibrotic activity in patients with chronic hepatitis C infection. Gastroenterology. Philadelphia: W B Saunders co-Elsevier Inc, 2010, vol. 138, No 4, p. 1365-1373. ISSN 0016-5085. |
Other formats:
BibTeX
LaTeX
RIS
@article{894365,
author = {McHutchinson, John and Goodman, Zachary and Patel, Keyur and Maklouf, Hala and RodriguezandTorres, Maribel and Schiffman, Mitchel and Rockey, Ron and Husa, Petr and Chuang, WanandLong and Levine, Robert and Jonas, Mark and Dickens, Theodore and Brigandi, Richard and Webster, Alison and Schultz, Margaret and Watson, Helen and Stancil, Britt and Gardner, Stephan},
article_location = {Philadelphia},
article_number = {4},
keywords = {Peroxisome Proliferator-Activated Receptor-gamma;Fibrosis;Treatment;Smooth Muscle Actin},
language = {eng},
issn = {0016-5085},
journal = {Gastroenterology},
title = {Farglitazar lacks antibrotic activity in patients with chronic hepatitis C infection},
volume = {138},
year = {2010}
}
TY - JOUR
ID - 894365
AU - McHutchinson, John - Goodman, Zachary - Patel, Keyur - Maklouf, Hala - Rodriguez-Torres, Maribel - Schiffman, Mitchel - Rockey, Ron - Husa, Petr - Chuang, Wan-Long - Levine, Robert - Jonas, Mark - Dickens, Theodore - Brigandi, Richard - Webster, Alison - Schultz, Margaret - Watson, Helen - Stancil, Britt - Gardner, Stephan
PY - 2010
TI - Farglitazar lacks antibrotic activity in patients with chronic hepatitis C infection
JF - Gastroenterology
VL - 138
IS - 4
SP - 1365
EP - 1365
PB - W B Saunders co-Elsevier Inc
SN - 00165085
KW - Peroxisome Proliferator-Activated Receptor-gamma;Fibrosis;Treatment;Smooth Muscle Actin
N2 - Farglitazar (GI262570), an insulin-sensitizing agent, selectively binds and activates peroxisome proliferator-activated receptor gamma (PPAR gamma) and inhibits stellate cell activation. We evaluated its antifibrotic effect in patients with chronic hepatitis C that did not respond to standard-of-care therapy. Patients with fibrosis of Ishak stages 2-4 (n = 265), were randomly assigned to groups given once-daily doses of 0.5 mg farglitazar, 1.0 mg farglitazar, or placebo for 52 weeks; repeat liver biopsy samples were then obtained. 209 patients had paired biopsy specimens adequate for analysis (81.5% with pretreatment Ishak scores of stage 2 or 3). There was no overall difference in SMA (P = .58) or collagen (P = .99) levels at week 52. In patients with chronic hepatitis C and moderate fibrosis, 52 weeks of treatment with farglitazar does not affect stellate cell activation or fibrosis (measured by morphometry or comparison of paired biopsy specimens
ER -
MCHUTCHINSON, John, Zachary GOODMAN, Keyur PATEL, Hala MAKLOUF, Maribel RODRIGUEZ-TORRES, Mitchel SCHIFFMAN, Ron ROCKEY, Petr HUSA, Wan-Long CHUANG, Robert LEVINE, Mark JONAS, Theodore DICKENS, Richard BRIGANDI, Alison WEBSTER, Margaret SCHULTZ, Helen WATSON, Britt STANCIL and Stephan GARDNER. Farglitazar lacks antibrotic activity in patients with chronic hepatitis C infection. \textit{Gastroenterology}. Philadelphia: W B Saunders co-Elsevier Inc, 2010, vol.~138, No~4, p.~1365-1373. ISSN~0016-5085.
|
